1.Ocular Abnormality of Korean Patients with Molecular Genetically Confirmed Gaucher Disease.
Sangmoon LEE ; Hyon J KIM ; Seon Yong JEONG ; Jeong Min HWANG
Journal of the Korean Ophthalmological Society 2013;54(1):131-135
PURPOSE: To investigate the ophthalmologic manifestations of Korean patients with Gaucher disease. METHODS: Clinical records of 5 patients who were referred to the pediatric ophthalmology clinic of Seoul National University Bundang Hospital after diagnosis of Gaucher disease at the genetics clinic of Ajou University Hospital between 2007 and 2008 were retrospectively reviewed. RESULTS: Five patients with type 3 Gaucher disease had hepatosplenomegaly and oculomotor apraxia, and 4 patients had growth and developmental delay. The most commonly detected genetic mutation was L444P. In addition, P201H, F2131, R257Q, and D315E+Rec 1b were identified. Five patients had oculomotor apraxia and limitation of abduction, and 4 patients had esotropia. One of the 4 patients who showed combined limitation of abduction, oculomotor apraxia, and esotropia, yet did not have growth and developmental delay. CONCLUSIONS: Most of the patients who were referred for ocular motor abnormalities with Gaucher disease showed a limitation of abduction, oculomotor apraxia, and esotropia. In patients with a limitation of abduction, oculomotor apraxia, and esotropia, Gaucher disease should be considered. Ophthalmologic examination is essential for subtyping and prognosing Gaucher disease.
Apraxias
;
Diagnosis
;
Esotropia
;
Gaucher Disease*
;
Genetics
;
Growth and Development
;
Humans
;
Lysosomal Storage Diseases
;
Ophthalmology
;
Retrospective Studies
;
Seoul
2.Treatment and management of patients with inherited metabolic diseases.
Korean Journal of Pediatrics 2006;49(11):1152-1157
Inherited metabolic disease is rare disorders that show symptoms mainly in pediatric age and early treatment is important for preventing complications of the disease. Recent development in molecular and biochemical techniques help clinicians with proper diagnosis of patients, however, many of the disease still remain lack of effective therapeutic strategies. Better understanding on biochemical and molecular basis of pathogenesis of the disease combined with advanced medical care would provide new sight on the disease that can also improve the quality of life and long-term prognosis of patients. Traditionally, there are several modalities in the treatment of metabolic diseases depend on the biochemical basis of the disease such as diet restriction, removing or blocking the production of toxic metabolites, and stimulating residual enzyme activity. The inherited metabolic disease is not familiar for many clinicians because the diagnosis is troublesome, treatment is complicated and prognosis may not as good as expected in other diseases. Recently, new therapeutic regimens have been introduced that can significantly improve the medical care of patients with metabolic disease. Enzyme replacement therapy has showed promising efficacy for lysosomal storage disease, bone marrow transplantation is effective in some disease and gene therapy has been trying for different diseases. The new trials for treatment of the disease will give us promising insight on the disease and most clinicians should have more interest in medical progress of the metabolic disease.
Bone Marrow Transplantation
;
Diagnosis
;
Diet
;
Enzyme Replacement Therapy
;
Genetic Therapy
;
Humans
;
Lysosomal Storage Diseases
;
Metabolic Diseases*
;
Metabolism
;
Prognosis
;
Quality of Life
3.A Case of Cystinosis.
Min Ho JUNG ; Seung On KEUN ; Soon Ju LEE ; Byung Churl LEE
Journal of the Korean Pediatric Society 2003;46(6):615-619
Cystinosis, an autosomal recessively inherited lysosomal storage disease, results from impaired transport of the amino acid cystine out of cellular lysosomes. The consequent accumulation and crystallization of cystine destroys tissues, causing growth retardation, Fanconi syndrome, renal failure, eye problems, and endocrinopathies. The gene for cystinosis, CTNS, was mapped to chromosome 17p13. The diagnosis of cystinosis was made by measuring the leukocyte cystine content. The presence of typical corneal crystals on slit-lamp examination is also diagnostic. Since treatment with cysteamine has proved extremely effective, early diagnosis and treatment are critical aspects. We experienced a typical case of cystinosis in a 12-year-old boy with growth retardation.
Child
;
Crystallization
;
Cysteamine
;
Cystine
;
Cystinosis*
;
Diagnosis
;
Early Diagnosis
;
Fanconi Syndrome
;
Humans
;
Leukocytes
;
Lysosomal Storage Diseases
;
Lysosomes
;
Male
4.Long-term clinical course of a patient with mucopolysaccharidosis type IIIB.
Ja Hye KIM ; Yang Hyun CHI ; Gu Hwan KIM ; Han Wook YOO ; Jun Hwa LEE
Korean Journal of Pediatrics 2016;59(Suppl 1):S37-S40
Mucopolysaccharidosis type III (MPS III) is a rare genetic disorder caused by lysosomal storage of heparan sulfate. MPS IIIB results from a deficiency in the enzyme alpha-N-acetyl-D-glucosaminidase (NAGLU). Affected patients begin showing behavioral changes, progressive profound mental retardation, and severe disability from the age of 2 to 6 years. We report a patient with MPS IIIB with a long-term follow-up duration. He showed normal development until 3 years. Subsequently, he presented behavioral changes, sleep disturbance, and progressive motor dysfunction. He had been hospitalized owing to recurrent pneumonia and epilepsy with severe cognitive dysfunction. The patient had compound heterozygous c.1444C>T (p.R482W) and c.1675G>T (p.D559Y) variants of NAGLU. Considering that individuals with MPS IIIB have less prominent facial features and skeletal changes, evaluation of long-term clinical course is important for diagnosis. Although no effective therapies for MPS IIIB have been developed yet, early and accurate diagnosis can provide important information for family planning in families at risk of the disorder.
Diagnosis
;
Epilepsy
;
Family Planning Services
;
Follow-Up Studies
;
Heparitin Sulfate
;
Humans
;
Intellectual Disability
;
Lysosomal Storage Diseases
;
Mucopolysaccharidoses*
;
Mucopolysaccharidosis III*
;
Pneumonia
5.Endocrine complications during and after adolescence in a patient with cystinosis.
Moon Bae AHN ; Sung Eun KIM ; Won Kyoung CHO ; Min Ho JUNG ; Byung Kyu SUH
Annals of Pediatric Endocrinology & Metabolism 2016;21(3):174-178
Cystinosis is a rare disease characterized by abnormal lysosomal cystine accumulation of cystine due to impaired lysosomal transport. We previously reported the first case of cystinosis in Korea in a 12-year-old boy with short stature, general weakness, and photophobia. The diagnosis was confirmed based on ophthalmic findings and biochemical analyses (serum leukocyte cystine measurement). Major endocrine manifestations at diagnosis included hypothyroidism, growth retardation, and hypogonadism. Despite oral cysteamine administration and renal replacement therapy, multiple complications including both endocrine and nonendocrine disorders developed during and after adolescence. In this report, we review the presenting features and factors related to the long-term complications in a patient with cystinosis.
Adolescent*
;
Child
;
Cysteamine
;
Cystine
;
Cystinosis*
;
Diagnosis
;
Humans
;
Hypogonadism
;
Hypothyroidism
;
Korea
;
Leukocytes
;
Lysosomal Storage Diseases
;
Male
;
Photophobia
;
Rare Diseases
;
Renal Replacement Therapy
6.Use of Tandem Mass Spectrometry for Newborn Screening of 6 Lysosomal Storage Disorders in a Korean Population.
Minje HAN ; Sun Hee JUN ; Sang Hoon SONG ; Kyoung Un PARK ; Jin Q KIM ; Junghan SONG
The Korean Journal of Laboratory Medicine 2011;31(4):250-256
BACKGROUND: We evaluated the performance of multiplex tandem mass spectrometry (MS/MS) in newborn screening for detection of 6 lysosomal storage disorders (LSDs), namely, Niemann-Pick A/B, Krabbe, Gaucher, Fabry, and Pompe diseases and Hurler syndrome. METHODS: We revised the conditions and procedures of multiplex enzyme assay for the MS/MS analysis and determined the precision of our enzyme assay and the effects of sample amounts and incubation time on the results. We also measured the degree of correlation between the enzyme activities in the dried blood spots (DBSs) and those in the leukocytes. DBSs of 211 normal newborns and 13 newborns with various LSDs were analyzed using our revised methods. RESULTS: The intra- and inter-assay precisions were 2.9-18.7% and 8.1-18.1%, respectively. The amount of product obtained was proportional to the DBS eluate volume, but a slight flattening was observed in the product vs. sample volume curve at higher sample volumes. For each enzyme assay, the amount of product obtained increased linearly with the incubation period (range, 0-24 hr). Passing and Bablok regression analysis revealed that the enzyme activities in the DBSs and those in the leukocytes were favorably correlated. The enzyme activities measured in the DBSs were consistently lower in patients with LSDs than in normal newborns. CONCLUSIONS: The performance of our revised techniques for MS/MS detection and enzyme assays was of the generally acceptable standard. To our knowledge, this is the first report on the use of MS/MS for newborn screening of LSDs in an Asian population.
Dried Blood Spot Testing
;
Enzyme Assays
;
Enzymes/blood
;
Humans
;
Infant, Newborn
;
Leukocytes/enzymology
;
Lysosomal Storage Diseases/*diagnosis
;
Republic of Korea
;
Tandem Mass Spectrometry/*methods
;
Time Factors
7.Detection of vacuolated peripheral blood lymphocytes in screening for and diagnosis of lysosomal storage diseases.
Xing-zhi CHANG ; Jie-yu LIU ; Ye WU ; Yu-wu JIANG ; Hui XIONG ; Shuang WANG ; Jiong QIN
Chinese Journal of Pediatrics 2011;49(2):135-138
OBJECTIVELysosomal storage diseases are a group of inherited disorders caused by deficiency of lysosomal enzymes or structural components. The manifestations of lysosomal storage diseases are complicated due to different enzyme deficiency. It has been reported that a range of metabolic diseases resulting in abnormal accumulation of metabolic byproducts may exhibit abnormal cytoplasmic vacuolation of lymphocytes. The aim of this study was to elicit the usefulness of vacuolated peripheral lymphocytes detection in screening and diagnosis of lysosomal storage diseases.
METHODClinical data of 42 patients who underwent microscopic and electron microscopic examination of peripheral blood specimens in our department were retrospectively evaluated between January 2008 and December 2009.
RESULTForty-two patients with the suspected lysosomal storage diseases were included, these patients presented with motor and developmental retardation and/or regression. Seizure occurred in 32 patients. Hepatosplenomegaly were found in 4 patients. Three patients presented with declined visual acuity. Atrophy and/or abnormal signals were detected on cranial CT/MRI images in 24 patients. Blood biochemical tests were normal. Serum levels of ammonia, lactic acid and pyruvate were normal. Serum amino acid profiles and urinary organic acid profiles were normal. Serum fatty acid profiles were normal. Vacuolated lymphocytes were detected on microscopic examination of blood film in 14 patients, and 8 of these patients were confirmed to have lysosomal storage disease. Curvilinear body was found on electronic microscopic examination of peripheral lymphocytes specimens in 4 patients, confirming the diagnosis of neuronal ceroid lipofuscinosis. In 3 of these 4 patients, curvilinear body were also found on electronic microscopic examination of skin and/or muscle specimens. Enzyme analysis confirmed the diagnosis of metachromatic leukodystrophy in one patient and Pompe's disease in another patient. Typical pathological changes were found on the examination of bone marrow in 2 patients with normal acid sphingomyelinase activity. So the patients were diagnosed with Niemann-Pick disease type C. The diagnosis of other 6 patients with vacuolated lymphocytes was unknown.
CONCLUSIONBecause of its usefulness and minimal invasiveness, vacuolated peripheral lymphocytes examination should be a screening test for lysosomal storage disease. As for patients with suspected neuronal ceroid lipofuscinosis, electron microscopic examination of peripheral lymphocyte specimens may provide specific clues to the final diagnosis.
Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Lymphocytes ; pathology ; Lysosomal Storage Diseases ; blood ; diagnosis ; pathology ; Male ; Microscopy, Electron ; Retrospective Studies ; Vacuoles
8.Substrate reduction therapy in three patients with Gaucher disease.
Soo Hyun KIM ; Eungu KANG ; Yoon Myung KIM ; Gu Hwan KIM ; In Hee CHOI ; Jin Ho CHOI ; Han Wook YOO ; Beom Hee LEE
Journal of Genetic Medicine 2016;13(2):72-77
PURPOSE: Gaucher disease (GD) is the most common lysosomal storage disease caused by beta-glucocerebrosidase (GBA) deficiency. Oral substrate reduction therapy with miglustat (Zavesca®) was approved for the treatment of adults with GD type 1, for whom enzyme replacement therapy (ERT) is unsuitable or not a therapeutic option. In this study, we report the effect of miglustat (Zavesca®) in three Korean GD patients. MATERIALS AND METHODS: Clinical findings comprising age at diagnosis, presenting signs, laboratory findings at diagnosis, GBA activity and mutations, and clinical courses of the three patients were reviewed. RESULTS: Miglustat was administered to three patients who reported allergic reactions during intravenous imiglucerase infusions. One patient withdrew after 15 months of miglustat administration owing to continuous elevation of disease biomarker levels (chitotriosidase, acid phosphatase, and angiotensin-converting enzyme). Poor adherence to medication was suspected but was denied by the patient. In the other two patients, platelet count and levels of hemoglobin and other biomarkers remained stable during miglustat administration. However, they suffered from severe diarrhea and weight loss, which led to miglustat discontinuation after 1 and 12 months of administration. CONCLUSION: Our study shows that although miglustat is suggested to GD patients as an alternative treatment to ERT, significant adverse reactions may lead to discontinuation of miglustat. In addition, it is difficult to monitor the drug adherence.
Acid Phosphatase
;
Adult
;
Biomarkers
;
Diagnosis
;
Diarrhea
;
Enzyme Replacement Therapy
;
Gaucher Disease*
;
Glucosylceramidase
;
Humans
;
Hypersensitivity
;
Lysosomal Storage Diseases
;
Platelet Count
;
Weight Loss
9.A family with two children diagnosed with aspartylglucosaminuria-case report and literature review.
Yujie LIU ; Liping ZOU ; Yan MENG ; Ying ZHANG ; Xiuyu SHI ; Jun JU ; Guang YANG ; Linyan HU ; Xiaoqiao CHEN
Chinese Journal of Pediatrics 2014;52(6):455-459
OBJECTIVEThe authors sought to investigate the clinical features and characteristics of genetic mutation in patients with aspartylglucosaminuria.
METHODClinical data of two pediatric siblings in a family were analyzed retrospectively and relative literature was reviewed in order to study the clinical features, imaging and enzymatic characteristics and genetic mutations.
RESULTCase 1, the proband, male, he was hospitalized at 20 months of age because of fever and hepatosplenomegaly for nine days. This child was of moderate nutritional status and normal development. Blood tests showed hemoglobin 78.0 g/L, RBC3.18 × 10¹²/L, WBC 4.06 × 10⁹/L, neutrophils 0.236, lymphocytes 0.631, platelets 34 × 10⁹/L, C-reactive protein 17 mg/L. Blood biochemistry showed alanine aminotransferase 67.1 U/L, aspartate aminotransferase 74.1 U/L, serum albumin 32.8 g/L, direct bilirubin 10.5 µmol/L, lactate dehydrogenase 301.7 U/L. Bone marrow cytology showed reactive morphological changes in bone marrow cells. Atypical lymphocytes could be seen in both peripheral blood and bone marrow smears. Cranial MRI showed poor myelination. Aspartylglucosaminidase activity in peripheral leucocytes of the proband 5.7 nmol/(g × min) vs. normal control>26.6 nmol/(g × min). On his AGA gene and that of his parents, a heterozygous mutation site located in exon 3, c.392C>T (p.S131L), was identified as a novel mutation inherited from his father. The mutation from his mother has not been detected. The proband was not responsive to the anti-infectious medication, nutritional intervention and symptomatic treatment.He died one month after diagnosis.His elder brother, Case 2, showed fever, recurrent respiratory tract infection and progressive psychomotor regression with hepatosplenomegaly from the age of four years. Cranial MRI revealed extensive symmetrical leukodystrophy in bilateral cerebra, cerebellum and brainstem.He died at the age of six years.Related literature was summarized, and no Chinese AGU cases had been reported; 221 foreign cases were collected. The clinical and imaging characteristics were summarized. Delay in language development was one of the clinical symptoms that the majority of parents of AGU children first noted.
CONCLUSIONPatients with aspartylglucosaminuria lack of specific symptoms.For children with unexplained delayed speech and progressive mental retardation, the possibility of AGU should be considered, and efforts be made for enzymatic and genetic diagnosis. c.392C> T (p.S131L) was identified as a novel mutation of AGA gene.
Aspartylglucosaminuria ; diagnosis ; genetics ; pathology ; Aspartylglucosylaminase ; genetics ; metabolism ; Biomarkers ; blood ; Brain ; pathology ; Child, Preschool ; DNA Mutational Analysis ; Heterozygote ; Humans ; Infant ; Lysosomal Storage Diseases ; diagnosis ; genetics ; pathology ; Magnetic Resonance Imaging ; Male ; Mutation ; Pedigree ; Polymerase Chain Reaction
10.Birth of a healthy baby after preimplantation genetic diagnosis in a carrier of mucopolysaccharidosis type II: The first case in Korea
Duck Sung KO ; Sun Hee LEE ; Chan Woo PARK ; Chun Kyu LIM
Clinical and Experimental Reproductive Medicine 2019;46(4):206-210
Mucopolysaccharidosis type II (MPS II) is a rare X-linked recessive lysosomal storage disease caused by mutation of the iduronate-2-sulfatase gene. The mutation results in iduronate-2-sulfatase deficiency, which causes the progressive accumulation of heparan sulfate and dermatan sulfate in cellular lysosomes. The phenotype, age of onset, and symptoms of MPS II vary; accordingly, the disease can be classified into either the early-onset type or the late-onset type, depending on the age of onset and the severity of the symptoms. In patients with severe MPS II, symptoms typically first appear between 2 and 5 years of age. Patients with severe MPS II usually die in the second decade of life although some patients with less severe disease have survived into their fifth or sixth decade. Here, we report the establishment of a preimplantation genetic diagnosis (PGD) strategy using multiplex nested polymerase chain reaction, direct sequencing, and linkage analysis. Unaffected embryos were selected via the diagnosis of a single blastomere, and a healthy boy was delivered by a female carrier of MPS II. This is the first successful application of PGD in a patient with MPS II in Korea
Age of Onset
;
Blastomeres
;
Dermatan Sulfate
;
Diagnosis
;
Embryonic Structures
;
Female
;
Heparitin Sulfate
;
Humans
;
Korea
;
Lysosomal Storage Diseases
;
Lysosomes
;
Male
;
Mucopolysaccharidoses
;
Mucopolysaccharidosis II
;
Multiplex Polymerase Chain Reaction
;
Parturition
;
Phenotype
;
Polymerase Chain Reaction
;
Preimplantation Diagnosis
;
Prostaglandins D